"and an HR of 0.67 in interim overall survival aren't marginal results"
One of the slide in the linked ppt http://www.unich.it/mso.cinbo/eng/courses/2006/2006111617slides/1711am/13_Ciardiello.ppt showed a hazard ratio of 0.84 with p=0.12, was this after ealy stopping followed by taxol patients cross-over. Will this BLA update the long term OS data? Given what's shown here, at 50% information, the liklihood of final OS significant would be very low. Perhaps FDA saw this coming at time of first review?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.